-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive question and answer session at the Emerging Growth Conference
STATEN ISLAND, N.Y., Jan. 16, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, is pleased to announce that it has been invited to present at the Emerging Growth Conference on January 25, 2023. This live, interactive online event will provide existing stockholders and the investment community with the opportunity to interact with the Company's President & Chief Executive Officer, David P. Luci, in real time. Mr. Luci will conduct an interview and open the floor for questions. Please submit your questions in advance to [email protected] or ask your questions during the event and Mr. Luci will do his best to respond to as many as possible.
Details of this event are as follows:
Date: | Wednesday, January 25, 2023 |
Time: | 9:40 am to 10:10 am Eastern Time |
Webcast: |
This live, interactive online event will provide current stockholders and the investment community the opportunity to interact with David P. Luci. As time permits, Mr. Luci may be able to respond to questions from participants.
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, We will release a link to that after the event.
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing an entirely new class of antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2021, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & CEO
Tel: 917-533-1469
Email: [email protected]
SOURCE Acurx Pharmaceuticals, Inc.
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive question and answer session at the Emerging Growth Conference
Acurx邀请个人和机构投资者、财务顾问和分析师参加其在新兴增长大会上的实时互动问答环节
STATEN ISLAND, N.Y., Jan. 16, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, is pleased to announce that it has been invited to present at the Emerging Growth Conference on January 25, 2023. This live, interactive online event will provide existing stockholders and the investment community with the opportunity to interact with the Company's President & Chief Executive Officer, David P. Luci, in real time. Mr. Luci will conduct an interview and open the floor for questions. Please submit your questions in advance to [email protected] or ask your questions during the event and Mr. Luci will do his best to respond to as many as possible.
纽约州斯塔顿岛,2023年1月16日亚洲网加利福尼亚州圣何塞1月25日电临床阶段生物制药公司Acurx PharmPharmticals,Inc.(纳斯达克市场代码:ACXP)(以下简称“Acurx”或“公司”)高兴地宣布,它已受邀在2023年1月25日举行的Emerging Growth Conference上发言。这一现场互动的在线活动将为现有股东和投资界提供与公司首席执行官总裁互动的机会,David·P·卢西,实时地。卢西将接受采访,并开始接受提问。请提前将您的问题提交到[受电子邮件保护]或者在活动期间询问您的问题,Luci先生将尽其所能回答尽可能多的问题。
Details of this event are as follows:
是次活动详情如下:
Date: |
Wednesday, January 25, 2023 |
Time: |
9:40 am to 10:10 am Eastern Time |
Webcast: |
日期: |
2023年1月25日(星期三) |
时间: |
东部时间上午9:40至10:10 |
网络直播: |
This live, interactive online event will provide current stockholders and the investment community the opportunity to interact with David P. Luci. As time permits, Mr. Luci may be able to respond to questions from participants.
这一现场互动的在线活动将为目前的股东和投资界提供与David·P·卢西互动的机会。如果时间允许,卢西先生或许能够回答与会者的问题。
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, We will release a link to that after the event.
如果与会者无法在大会当天现场观看活动,EmergingGrowth.com和Emerging Growth YouTube频道也将提供存档的网络直播,我们将在活动结束后发布链接。
About the Emerging Growth Conference
关于新兴增长大会
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
新兴增长会议是上市公司从其办公室方便地、以高效的方式向投资界介绍和传达其新产品、服务和其他重大公告的有效方式。
The Conference focus and coverage includes companies in a wide range of growth sectors with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
会议的重点和报道范围包括广泛的成长型行业中的公司,这些公司拥有强大的管理团队、创新的产品和服务、专注的战略、执行和长期增长的整体潜力。它的受众可能包括数以万计的个人和机构投资者,以及投资顾问和分析师。
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
所有会议将通过视频网络广播进行,并将在东部时区举行。
About Acurx Pharmaceuticals, Inc.
Acurx制药公司简介
Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing an entirely new class of antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit
Acurx制药公司是一家临床阶段的生物制药公司,专注于开发一种全新的抗生素类别,用于治疗难治性感染。该公司的方法是开发针对DNA聚合酶IIIC酶的抗生素候选产品,其研发流水线包括针对革兰氏阳性菌的抗生素候选产品,包括艰难梭菌、耐甲氧西林金黄色葡萄球菌(MRSA)、万古霉素耐药肠球菌(VRE)和耐药肺炎链球菌(DRSP)。欲了解更多有关Acurx制药公司及其产品线的信息,请访问
Forward-Looking Statements
前瞻性陈述
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2021, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
本新闻稿中有关我们未来预期、计划和展望的任何声明,包括有关我们的战略、未来业务、前景、计划和目标的声明,以及包含“相信”、“预期”、“计划”、“预期”和类似表述的其他声明,均属“1995年私人证券诉讼改革法”所指的前瞻性声明。由于各种重要因素,实际结果可能与前瞻性陈述中显示的结果大不相同,这些因素包括:ibezapolstat是否将受益于QIDP的指定;ibezapolstat是否会及时通过临床试验过程;ibezapolstat的临床试验结果是否将保证提交上市批准申请;如果是,ibezapolstat是否会获得FDA或寻求批准的同等外国监管机构的批准;如果ibezapolstat获得批准,它是否会成功地分发和上市;以及公司在提交给证券交易委员会的截至2021年12月31日的10-K表格年度报告以及公司随后提交给证券交易委员会的文件中描述的其他风险和不确定性。此类前瞻性陈述仅在本新闻稿发布之日发表,Acurx没有任何更新这些前瞻性陈述以反映此类陈述之后的事件或情况的意图或义务,除非法律另有要求。
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & CEO
Tel: 917-533-1469
Email: [email protected]
投资者联系方式:
Acurx制药公司
David·P·卢西,总裁兼首席执行官
电话:917-533-1469
电子邮件:[受电子邮件保护]
SOURCE Acurx Pharmaceuticals, Inc.
资料来源:Acurx制药公司
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧